Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T12:50:44.087Z.
Calculation as of: 2026-10-06T12:50:44.087Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1148a26bf5d8a77c385830e28adfe1a3226667ff180e3eaa52d15dba3998f7d4
PE RATIO
N/A
Market Cap
$1.02M
PE Ratio
N/A
TTM Avg
173046.93
3Y Avg
281427.36
5Y Avg
281427.36
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bluejay Diagnostics, Inc. (BJDX) | $787624.00 | N/A | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $707297.00 | N/A | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $878396.00 | N/A | 0.00 | 0.00 | 0.00 |
| GlucoTrack, Inc. (GCTK)vs › | $885939.00 | N/A | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $888387.00 | N/A | N/A | N/A | N/A |
| HCW Biologics Inc. (HCWB)vs › | $570131.00 | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | N/A | 173046.93 | 281427.36 | 281427.36 |
| Clearmind Medicine Inc. (CMND)vs › | $1.11M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.14M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.76
Forward EPS (Est.)
$-464.00
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
